EGFR and cancer: To assess the validity of this corrective algorithm, we applied the proposed normalization method to the quantification of EGFR, HER2 and HER3 in samples with decreasing RNA integrity obtained from two model-independent cancer cell lines (LS174T, colon; SKBr3, breast).